# Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

> **NCT05392647** · PHASE2 · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Hetrombopag

## Key facts

- **NCT ID:** NCT05392647
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392647, "Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05392647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*